Inhibiting Tyrosine Kinase 2 Ameliorates Antiphospholipid Syndrome Nephropathy
Conclusion: Our results demonstrated the key role of type I IFN in the pathogenesis of APS nephropathy. Furthermore, the therapeutic efficacy of Tyk2 inhibition was demonstrated in a murine model of APS nephropathy. Our results could provide a new treatment strategy for this debilitating disease.
Saved in:
| Main Authors: | Kuo-Tung Tang, Yu-Sin Chen, Tzu-Ting Chen, Ya-Hsuan Chao, Shu-Ping Kung, Der-Yuan Chen, Chi-Chien Lin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/mi/5568822 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Baicalin and Baicalein Inhibit Src Tyrosine Kinase and Production of IL-6
by: Dubravko Jelić, et al.
Published: (2016-01-01) -
Protein tyrosine kinase but not protein kinase C inhibition blocks receptor induced alveolar macrophage activation
by: K. Pollock, et al.
Published: (1993-01-01) -
TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01) -
TYROSINE KINASE INHIBITORS AND PREGNANCY
by: Elisabetta Abruzzese, et al.
Published: (2014-04-01) -
In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
by: Jihene Elloumi-Mseddi, et al.
Published: (2013-01-01)